louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04665102: Pilot Study on Deep Learning in the Eye
Official title: Validation of a Transfer Learning Deep Learning Algorithm for Image Classification in Multiple Pathologies
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Central Serous Chorioretinopathy
Diabetic Retinopathy
Cataract
Lead sponsor: CRG UZ Brussel
Sponsor class: OTHER
First posted: 2020-12-11
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy and non-healthy subjects: extract data out of available images

Brief summary: Deep learning allows you to classify images using a self-learning algorithm. Transfer learning builds on an existing self-learning algorithm to enable image classification with fewer images. In this study, this technique will be applied to different image modalities in different syndromes. Retrospective study design.


Eligibility criteria: Inclusion Criteria:

* Availability of images, which allow discrimination.

Exclusion Criteria:

* No availability of clear data on disease differentiation

Primary outcomes:
measure: Validation of Image classification by transfer learning algorithm
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03255902: Family Routines - Healthy Families
Official title: Family Routine - Healthy Families
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetes Mellitus, Type 1
Keywords: Diabetes
Lead sponsor: William Beaumont Hospitals
Sponsor class: OTHER
Collaborators: name: University of Michigan
First posted: 2017-08-21
Enrollment: 7
Sex: ALL
Minimum age (years): 2
Maximum age (years): 5
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: This feasibility study will be a mixed methods non-randomized trial to examine the feasibility of combining a parent skill training intervention with a family evening routine intervention. Evidence of feasibility will include attendance, activities completed, and interviews.
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of the proposed study, Family Routines - Healthy Families, is to examine the feasibility and acceptability of a parenting/family routine intervention program for parents of young children, ages 2-5, with type 1 diabetes.

Detailed description: The intervention in Family Routines - Healthy Families contains an established and effective parent skills training curriculum called "The Incredible Years," uniquely integrated with a newly developed family evening routine component e.g., family dinner time and evening routine, to promote improved metabolic control. The investigator will assess outcomes during and at one week post intervention. Outcome measures will include family routine, specifically the time between the dinner and bedtime glucose check, parent bedtime decision making, and child overnight glucose control. In addition, parental quality of life and receptiveness to the intervention will be assessed.

Eligibility criteria: Inclusion Criteria:

1. Self identification as primary care giver of child that fits following criteria:

   1. Age 2 - 5 years
   2. Diagnosis of Type 1 diabetes
   3. Most recent Hemoglobin A1c (HbA1c) \> 8.0
   4. Child a patient of Pediatric Endocrinology, Beaumont Children's Hospital
2. English fluency

Exclusion Criteria:

1. Cognitively impaired
2. Does not meet inclusion criteria

Primary outcomes:
measure: Effect of Intervention on Evening Glucose Control.
timeFrame: After 6 weeks of classes
Secondary outcomes:
measure: Difference Between Child's Pre-intervention and 3 Month Hemoglobin A1c Value
timeFrame: Pre intervention to 3 months post intervention
Other outcomes:
Locations:
Study officials:
affiliation: William Beaumont Children's Hospital
name: Donna Marvicsin, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06269302: Comparison of the Effect of Warfarin and Direct Oral Anticoagulants
Official title: Comparison of the Effect of Warfarin and Direct Oral Anticoagulants on Upper Gastrointestinal System Bleeding
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Anticoagulants and Bleeding Disorders
Gastrointestinal Hemorrhage
Keywords: Gastrointestinal System
Oral Anticoagulant
Rebleeding
upper gastrointestinal system bleeding
Lead sponsor: Samsun Education and Research Hospital
Sponsor class: OTHER
First posted: 2024-02-21
Enrollment: 346
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients who were admitted to Samsun Training and Research Hospital with a diagnosis of upper gastrointestinal bleeding and hospitalized by Internal Medicine and Gastroenterology clinics or who underwent outpatient endoscopy were included in the study.

Brief summary: In this study, it was aimed to compare the frequency of new oral anticoagulants and warfarin usage, and to reveal the rates of recurrent upper gastrointestinal bleeding among patients who applied to our hospital with upper gastrointestinal bleeding

Detailed description: The data of all patients who applied to Samsun Training and Research Hospital Internal Medicine with a diagnosis of upper gastrointestinal bleeding and hospitalized by Internal Medicine and Gastroenterology clinics or who underwent outpatient endoscopy between 01.01.2021 and 31.12.2021 were included. The patients' data were analyzed from the patient files and hospital automation system retrospectively. Patients who had recurrent upper GI bleeding were detected by controlling them over the hospital software system and by reaching each patient again. The frequency of the new generation oral anticoagulants usage in patients with re-bleeding was determined, and data such as re-bleeding rate, length of hospital stay, need for transfusion, and mortality were analyzed in the groups who did not use this drug and those who used it. The patient demographics were also compared between the groups who were using the new generation oral anticoagulants, acetylsalicylic acid or warfarin.

Eligibility criteria: Inclusion Criteria:

* Age \>18 years old
* Upper gastrointestinal bleeding
* 12 months follow-up

Exclusion Criteria:

* Age \<18 years old
* Lower gastrointestinal bleeding
* Esophageal variceal bleeding

Primary outcomes:
measure: Change in the incidence of recurrent bleeding
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Samsun
country: Turkey
facility: Samsun Education and Research Hospital
state: İlkadım
Study officials:
affiliation: Samsun Education and Research Hospital
name: DÜRİYE SILA KARAGÖZ ÖZEN, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01091402: Autologous Serum Skin Test and Serum IL-18 Levels in Chronic Idiopathic Urticaria and Respiratory Allergic Diseases
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Urticaria
Respiratory Allergic Diseases
Keywords: autologous serum skin test, IL-18
Lead sponsor: Eskisehir Osmangazi University
Sponsor class: OTHER
First posted: 2010-03-24
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients from Outpatient clinic

Brief summary: One of the proposed mechanisms in CU is autoimmunity. It was shown by a positive response to autologous serum skin test (ASST)in almost half of chronic urticaria (CU) patients. IL-18 also play a role in autoimmune disorders. The investigators aim was to investigate the relationship of ASST and IL-18 in CU and respiratory allergic diseases.


Eligibility criteria: Inclusion Criteria:

* adult patients
* chronic urticaria patients
* stable asthma patients
* allergic rhinitis patients with sensitized to pollens
* normal controls without atopic and skin disease.

Exclusion Criteria:

* unwillingness to the study
* other dermatological problems that could affect the skin test
* use of antihistamine drugs

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Eskisehir
country: Turkey
facility: Eskisehir Osmangazi University
Study officials:
References:
Clinical trial NCT05408702: Exercise in Autoimmune Myasthenia Gravis and Myasthenic Syndromes
Official title: Barriers and Facilitators to Exercise for Individuals With Autoimmune Myasthenia Gravis, Congenital Myasthenic Syndrome or Lambert-Eaton Myasthenic Syndrome in France: a Descriptive, Cross-sectional Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Autoimmune Myasthenia Gravis
Lambert-Eaton Myasthenic Syndrome
Congenital Myasthenic Syndrome
Myasthenia Gravis
Lead sponsor: Institut de Myologie, France
Sponsor class: OTHER
Collaborators: name: Association Française contre les Myopathies (AFM), Paris
First posted: 2022-06-07
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adults living in France or its territories, with a confirmed diagnosis of MG or SMC or LEMS

Brief summary: A few recent observational studies show that despite the lack of clear recommendations, many individuals with myasthenia participate in exercise. However, no link has been found between exercise and the severity of myasthenia symptoms, measured by the Muscle Myasthenia Score or the Myasthenia Gravis Composite Score. This suggests that there are other factors that may limit or prevent some individuals from being active, or factors which may facilitate participation in exercise.

Studies in other diseases have shown that there are internal (beliefs, motivation, etc.) and external (cost, accessibility, etc.) factors unrelated to the disease which may play a role in exercise participation.

The aim of this study is to identify factors that facilitate or limit exercise in individuals with autoimmune myasthenia gravis, congenital myasthenia syndrome and Lambert-Eaton syndrome.


Eligibility criteria: Inclusion Criteria:

* at least 18 years old
* confirmed diagnosis of MG or SMC or LEMS
* Live in France or its territories
* Provide consent

Exclusion Criteria:

-

Primary outcomes:
measure: Barriers and facilitators to exercise
timeFrame: Six months
Secondary outcomes:
Other outcomes:
Locations:
city: Paris
country: France
facility: Online Questionnaire
Study officials:
References:
Clinical trial NCT06617702: Accountability Support Through Peer-Inspired Relationships and Engagement (ASPIRE) Trial
Official title: ASPIRE to Change: Leveraging Text Messaging Peer Support Coaching to Mitigate Hazardous Alcohol Consumption in Non-Collegiate Young Adults
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Alcohol Consumption
Keywords: alcohol
text message
young adults
peers
Lead sponsor: Stanford University
Sponsor class: OTHER
Collaborators: name: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
First posted: 2024-09-27
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Maximum age (years): 25
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This project aims to test the efficacy of a text message intervention, ASPIRE, designed to address cognitive and behavioral elements and modify exposure to peers that influence drinking behaviors. Young adults who are contemplating reducing their drinking will be recruited from a national sample and randomized to ASPIRE versus a text message intervention focused solely on cognitive and behavioral elements. We will measure effectiveness at 3, 6, and 12 months, study mechanisms driving behavior change, and identify which subgroups stand to benefit most.


Eligibility criteria: Inclusion Criteria:

* Age 18-25 years (verified using date of birth)
* Lives in the U.S. (based on zip code)
* English reader (verified based on completing screen)
* 2+ days with ≧4 standard alcohol drinks for women or ≧5 standard alcohol drinks for men in past month
* Owns a mobile phone with SMS (verified by texting enrollment procedure)

Exclusion Criteria:

* Currently enrolled or past enrollment in a 4-year college
* Active military
* Pregnant or pregnancy plans in the next 12-months
* Prisoner status
* Current or planned treatment for alcohol or substance use disorder in next 12-months

Primary outcomes:
measure: Number of Binge Drinking Days (BDD)
timeFrame: 3, 6, and 12 months
Secondary outcomes:
measure: Negative Alcohol Consequences (NAC) Scale Score
timeFrame: 3, 6 and 12 months
Other outcomes:
Locations:
city: Palo Alto
country: United States
facility: Stanford University
state: California
Study officials:
affiliation: Stanford University
name: Brian Suffoletto, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kahler CW, Hustad J, Barnett NP, Strong DR, Borsari B. Validation of the 30-day version of the Brief Young Adult Alcohol Consequences Questionnaire for use in longitudinal studies. J Stud Alcohol Drugs. 2008 Jul;69(4):611-5. doi: 10.15288/jsad.2008.69.611.
citation: Sobell LC, Brown J, Leo GI, Sobell MB. The reliability of the Alcohol Timeline Followback when administered by telephone and by computer. Drug Alcohol Depend. 1996 Sep;42(1):49-54. doi: 10.1016/0376-8716(96)01263-x.
citation: Rueger SY, Trela CJ, Palmeri M, King AC. Self-administered web-based timeline followback procedure for drinking and smoking behaviors in young adults. J Stud Alcohol Drugs. 2012 Sep;73(5):829-33. doi: 10.15288/jsad.2012.73.829.
Clinical trial NCT05100602: Clinical Evaluation of Genetron TERT PCR Kit in Glioma Patients
Official title: Clinical Evaluation of Genetron TERT PCR Kit in Glioma Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Glioma, Malignant
Lead sponsor: Genetron Health
Sponsor class: INDUSTRY
Collaborators: name: Huashan Hospital
name: Zhejiang University
name: West China Hospital
name: The First Hospital of Jilin University
First posted: 2021-10-29
Enrollment: 1192
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Hospital sample

Brief summary: The purpose of this trail is to evaluate the performance of Genetron TERT PCR Kit in Glioma patients using real-time PCR method.

Detailed description: This trial follows the principle of synchronous blinding. The enrolled cases are coded, and the enrolled samples are detected with the Genetron TERT PCR Kit and Sanger sequencing method. The results were determined independently according to the cutoff values or interpretation requirements provided by each method.Combined with the results of clinicopathological classification, the incidence of C228T and C250T mutations of TERT promoter genes in different subtypes was counted to evaluate the clinical application performance of the Genetron TERT PCR Kit.

Eligibility criteria: Inclusion Criteria:

1. Enroll cases in strict accordance with the requirements of the study
2. The remaining samples after routine clinical testing
3. The collection and processing of samples meet the requirements of standard laboratory operations and product instructions
4. The relevant information of the sample is complete, including sample number, gender, age, and possible clinical diagnosis information
5. Each sample must have HE staining results (hematoxylin-eosin staining)
6. Pathological examination diagnosed as glioma, other brain tumors or normal tissues
7. Number of samples: 10 pieces of each sample with a thickness of 10μm, and the tumor content is not less than 50%

Exclusion Criteria:

1. The sample information is not complete
2. Severely contaminated samples
3. Samples that do not meet the requirements of sample collection and processing

Primary outcomes:
measure: Efficacy of the Genetron TERT PCR Kit
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Jilin
country: China
facility: The First Hospital of Jilin University
city: Shanghai
country: China
facility: Huashan Hospital of Fudan University
city: Sichuan
country: China
facility: West China Hospital of Sichuan University
city: Zhejiang
country: China
facility: The Second Affiliated Hospital of Zhejiang University
Study officials:
References:
Clinical trial NCT01902602: Grand Autohemo-Therapy With Oxygen-ozone on Patients With Hypertonia
Official title: Grand Autohemo-Therapy With Oxygen-ozone on Patients With Hypertonia
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Hypertonia
Lead sponsor: Herrmann Apparatebau GmbH
Sponsor class: INDUSTRY
First posted: 2013-07-18
Enrollment: 19
Sex: ALL
Minimum age (years): 45
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients which fulfill the mentioned criterias.

Brief summary: The objective of this clinical study is to evaluate the influence of the Great autohemotherapy with oxygen-ozone (hyperbaric ozone therapy ) to describe the cardiovascular system in patients with resistant hypertension. The primary endpoint is the change in mean blood pressure after 10 treatments .

In addition, data are collected on the immune system as well as for food and sleep quality.


Eligibility criteria: Inclusion Criteria:

* Resistant Hypertension \> 140 / \> 90mmHg
* Inclusion age : 45 +
* Regular monitoring of blood levels considered
* pre-medication to lower blood pressure for at least 3 weeks before the preliminary investigation consistent
* Men and Women

Exclusion Criteria:

* derailed diabetes
* renal impairment , renal creatinine clear \<50 ml
* Non - austherapierte cancer / tumor patients
* Non - adjusted thyroid dysfunction
* BMI\> 35
* LVEF \<limit ( " 35% " )
* Peripheral AVK ( ABI - measurement ) \> Stage II
* regurgitation \> Stage I
* abdominal aneurysm
* infections
* acute febrile infections with temperature \> 38.5 ° C
* COPD and asthma to stage III
* dyspnea NYHA \> Stage III
* z.n. Stroke shorter than 12 weeks
* Acute liver failure
* Acute Apoplexy
* Severe poisoning
* drug addiction
* hyperthyroidism
* Hypotension
* hypocalcemia
* hypoglycemia
* ozone allergy
* pregnancy
* clotting problems ( hemophilia )
* pre-existing condition with hemoglobin \< 9mg/dl
* Fresh myocardial infarction
* Internal bleeding
* thrombocytopenia
* Acute alcohol
* Citrus allergy when using sodium citrate

Primary outcomes:
measure: Change of blood pressure
timeFrame: 3 months
Secondary outcomes:
measure: Change of pulse
timeFrame: 3 months
measure: Change of blood count, liver and nephrew values
timeFrame: 3 months
measure: Change of liver and nephrew values
timeFrame: 3 months
measure: Change of life and Sleeping quality
timeFrame: 3 months
Other outcomes:
Locations:
city: Biblis
country: Germany
facility: Dr. Panos Porikis
state: Hessen
Study officials:
affiliation: unafflicated
name: Panos Porikis, Phd
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06702202: Effect of Subarachnoid Block and Femoropopliteal Block to Limb Perfusion in PAD Patients
Official title: Comparison of the Effect of Subarachnoid Block and Femoropopliteal Block to Limb Perfusion in Patients with Peripheral Arterial Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Peripheral Arterial Disease
Subarachnoid Block
Femoropopliteal Block
Tissue Oxygen Saturation
Lead sponsor: Indonesia University
Sponsor class: OTHER
First posted: 2024-11-22
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This pilot study investigates the effects of femoropopliteal and subarachnoid nerve blocks on tissue oxygen saturation (StO2) in patients with Peripheral Arterial Disease (PAD) during lower limb surgeries. Using Near-Infrared Spectroscopy (NIRS), the study compares changes in StO2 post-block. Although no significant differences were found between the two block types at most time points, subarachnoid blocks generally led to higher StO2 increases compared to femoropopliteal blocks, with significant differences observed at 5 and 15 minutes post-block.

Detailed description: This pilot study explored the impact of femoropopliteal and subarachnoid nerve blocks on tissue oxygen saturation (StO2) in patients with Peripheral Arterial Disease (PAD) during lower limb surgeries, using Near-Infrared Spectroscopy (NIRS) for non-invasive monitoring. The study compared StO2 changes at baseline, 5, 15, and 30 minutes post-block in two groups: those receiving femoropopliteal blocks and those receiving subarachnoid blocks.

Eligibility criteria: Inclusion Criteria:

* Age 18-80 years old who are scheduled to undergo lower limb debridement surgery.
* Diagnosis of Peripheral Arterial Disease (PAD).
* Lesion located below the knee.

Exclusion Criteria:

* Consuming opioids before hospital admission.
* Having allergies to the medications used in the study.
* Presence of infection at the injection site.

Primary outcomes:
measure: Measurement of Tissue Oxygen Saturation (StO2)
timeFrame: TI (Baseline): 10 minutes before the intervention; T2: 5 minutes after the intervention; T3: 15 minutes after the intervention; T4: 30 minutes after the intervention
Secondary outcomes:
Other outcomes:
Locations:
city: Jakarta
country: Indonesia
facility: Cipto Mangunkusumo Cental National Hospital
state: DKI Jakarta
Study officials:
References:
Clinical trial NCT03526302: TroponinT After Subcutaneous Cardioverter-Defibrillator Implantation
Official title: Register About Change of hsTROPoninT After Implantation of a Subcutaneous Implantable Cardioverter-Defibrillator
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Sudden Cardiac Death
Lead sponsor: Deutsches Herzzentrum Muenchen
Sponsor class: OTHER
First posted: 2018-05-16
Enrollment: 43
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with the indication for the implantation of an entirely subcutaneous cardioverter-defibrillator

Brief summary: Serum Troponin levels pre- and postoperatively will be compared in patients receiving an entirely subcutaneous cardioverter-defibrillator.

Detailed description: To analyze the periprocedural myocardial damage the pre- and postoperative assessment of serum levels of high sensitive TroponinT (hsTnT) is done. The main objectives of the TROPIC register are to evaluate the level of high sensitive TroponinT before and after S-ICD device implantation and to compare these changes in TroponinT-levels with those after standard transvenous ICD-implantation.

Eligibility criteria: Inclusion Criteria:

* Indication for the implantation of an entirely subcutaneous cardioverter-defibrillator

Exclusion Criteria:

* None

Primary outcomes:
measure: High sensitive TroponinT
timeFrame: 24 hours
Secondary outcomes:
Other outcomes:
Locations:
city: München
country: Germany
facility: Deutsches Herzzentrum München
Study officials:
affiliation: Deutsches Herzzentrum München
name: Christof Kolb, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Weigand S, O'Connor M, Blazek P, Kantenwein V, Friedrich L, Grebmer C, Schaarschmidt C, von Olshausen G, Reents T, Deisenhofer I, Lennerz C, Kolb C. Release of high-sensitive TROPonin T by implantation of an entirely subcutaneous Implantable Cardioverter-defibrillator compared to a conventional transvenous approach: the TROPIC registry. J Interv Card Electrophysiol. 2021 Oct;62(1):75-81. doi: 10.1007/s10840-020-00874-z. Epub 2020 Sep 21.